Antifibrotic effect of AT-1 blocker and statin in rats with hepatic fibrosis.
Autor: | El-Ashmawy NE; Biochemistry Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt., El-Bahrawy HA; Biochemistry Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt., Shamloula MM; Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt., Ibrahim AO; Biochemistry Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt. |
---|---|
Jazyk: | angličtina |
Zdroj: | Clinical and experimental pharmacology & physiology [Clin Exp Pharmacol Physiol] 2015 Sep; Vol. 42 (9), pp. 979-987. |
DOI: | 10.1111/1440-1681.12446 |
Abstrakt: | Hepatic fibrosis is an outcome of chronic liver injury. Angiotensin II (ANG II) may play a role in the pathogenesis of hepatic fibrosis. Certain drugs such as ACE inhibitors, ANG II antagonists, and even statins could interfere with the renin angiotensin system and modulate its deleterious effects. This study was carried out to investigate the possible role of losartan and atorvastatin in liver fibrosis. Liver fibrosis was induced in rats by i.p. injection of 50% CCl (© 2015 Wiley Publishing Asia Pty Ltd.) |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |